(Q33385308)

English

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

object named as

B Fehse

11

0 references

author name string

M Lioznov

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J El-Cheikh

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F Hoffmann

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Hildebrandt

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F Ayuk

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Wolschke

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D Atanackovic

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Schilling

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Badbaran

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

U Bacher

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A R Zander

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D Blaise

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Mohty

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Kröger

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

6 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

349-353

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

21 January 2018

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

7 January 2021

based on heuristic

inferred from DOI database lookup

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.155

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2009.155

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33385308&oldid=2195309037"